The safety and adverse event profiles of treatment with VYDURA were assessed in studies of both acute and preventive treatment of migraine.^2,3

• More than 3800 unique subjects received VYDURA* in the Phase 2 and Phase 3 studies⁵
• The most common adverse reaction was nausea for acute treatment (1.2%) and for migraine prophylaxis (1.4%). Most of the reactions were mild or moderate in severity¹
• Hypersensitivity reactions, including dyspnoea and rash, have occurred in fewer than 1% of patients treated with VYDURA in clinical studies¹
• No serious adverse events were reported in the acute study (303) while less than 1% of subjects reported serious adverse events in the prevention study (305)^2,3
• 2% of patients experienced an adverse event that led to discontinuation of VYDURA* in the prevention study (305)³ 
• VYDURA is not contraindicated for patients who have cardiovascular risk factors¹

• The majority of adverse events were mild⁴
• Serious adverse events were reported in 47 (2.6%) subjects but none were considered to be related to VYDURA⁶*
• No clinically relevant laboratory abnormalities were observed⁶

D/C, discontinuation; ODT, orally disintegrating tablet; PRN, as required; QOD, every other day.
^*Patients received a rimegepant 75 mg tablet that was bioequivalent to VYDURA.^4,5
†Subjects treated with VYDURA* (i.e. safety population).^4
‡Scheduled QOD+PRN, every other day dosing plus as needed on non-scheduled dosing days for up to 12 weeks.⁴